Episode 19: ELIOS – What does the data tell us?

Robust Long-Term Data:

• Eight-year follow-up studies on ELIOS show sustained intraocular pressure (IOP) reduction (≈25–30%) and decreased medication use with a strong safety profile.
• These are among the longest follow-up results available for any MIGS procedure, confirming durable outcomes for both primary and pseudoexfoliative open-angle glaucoma.

Consistency Across Studies:

• Multiple independent centers (e.g., Zurich, Hamburg, Berlin) report similar efficacy and safety findings, reinforcing the reliability of ELIOS data.
• Combination with cataract surgery (phaco+ELIOS) tends to provide greater IOP and medication reduction than standalone ELIOS.

Safety and Surgical Advantages:

• The excimer laser’s non-thermal mechanism avoids tissue scarring, offering a gentle, implant-free approach that preserves the conjunctiva for potential future filtering surgery.
• Complication rates are minimal and comparable to standard cataract surgery.

Clinical and Patient Impact:

• Long-term data provide confidence for clinicians and reassurance for patients who seek sustainable glaucoma control.
• ELIOS is particularly suitable for mild-to-moderate glaucoma, effectively reducing medication burden while maintaining safety.

Future Direction:

• Continued data collection, randomized controlled trials, and real-world evidence will further strengthen the understanding of ELIOS efficacy and its role in glaucoma management.
• Ongoing research underscores the importance of robust peer-reviewed evidence in shaping clinical decisions and supporting adoption of interventional glaucoma approaches.